Zealthy review

Read this row before the price, not after. Zealthy's headline figure is genuinely among the cheapest on this entire board, quoted for a quarterly-prepay compounded plan with supplies included. Independently checked against fda.gov, the company's legal entity has received two separate FDA warning letters for marketing compounded semaglutide and tirzepatide with claims the agency found false or misleading — one in September 2025, a second in February 2026 after a follow-up review found the same problems continuing. Reported DOJ and FTC scrutiny concerns undisclosed subscription terms and difficulty cancelling, and the founder previously ran a company that settled with the FTC on similar grounds. None of that is a claim we are making ourselves — it is what the FDA's own public letters and independent reporting say — but a headline price this low, from a company with this record, is exactly the situation where reading past the number matters most.

Two FDA warning letters (2025-09-09 and 2026-02-20) for marketing compounded semaglutide and tirzepatide with claims the FDA found false or misleading — both letters are public at fda.gov

Zealthy (legal entity FitRX LLC, recently operating as Gronk Inc.) advertises compounded semaglutide at a headline price near the bottom of this board, filled through independent licensed prescribers in an asynchronous model that does not require a video visit. That low headline is the whole reason to read the rest of the row carefully: the FDA has sent FitRX LLC two separate warning letters for marketing compounded semaglutide and tirzepatide with false or misleading claims — one dated 2025-09-09 (letter 716501, addressed to "FitRX, LLC dba Zealthy") and a second dated 2026-02-20 (letter 717987, addressed to "FitRX, LLC dba FitRx") after a follow-up review found the same violations continuing. Independent reporting also describes an active Novo Nordisk trademark/false-advertising suit and DOJ/FTC scrutiny alleging undisclosed subscription terms and locked cancellation — consistent with the fact that Zealthy's own pricing page does not spell out whether $151/month is the whole bill. The founder previously ran Cerebral, which settled with the FTC in 2024 over comparable allegations.

Pricing structure

Varies by dose, plan or tier

Consult

Billed separately

Compounding pharmacy

Not publicly identified

Labs

Not required

Dietitian support

Not included

• ✓One of the lowest headline prices on this entire board
• ✓Serves a meaningful number of states with an asynchronous model that removes the friction of a scheduled video visit
• ✓Independent licensed prescribers retain clinical authority rather than a single in-house panel

• —Zealthy's own pricing page does not state whether $151/month is the complete monthly cost or whether another fee applies on top of it
• —Reported active DOJ/FTC scrutiny over subscription and cancellation practices, and an active Novo Nordisk trademark suit, per independent reporting
• —Compounded semaglutide is not the FDA-approved brand product, and the FDA's own letters concern claims made about exactly that distinction

Semaglutide is a prescription medicine, and the compounded version is not the same regulated product as brand-name Wegovy or Ozempic. Whatever you decide, decide it with a clinician who knows your history — and go into that conversation with real numbers.

• Where compounded semaglutide stands legally
• Is it worth it?
• What Wegovy actually costs
• Wegovy cost calculator
• Weight-loss projection calculator

Zealthy is one of 42 telehealth semaglutide programmes we track. The board puts every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to, rather than only in the small print.